Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zimmermann

Showing results (171-180 of 279) with videos related to

Pageof 28
Sort By:
Haematologica|August 10, 2012
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolPetra Dörge, Barbara Meissner, Martin Zimmermann, et al.
Pediatric Blood & Cancer|June 10, 2017
Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groupsUrsula Creutzig, Michael N Dworzak, Martin Zimmermann, et al.
Cancers|March 6, 2021
Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study GroupMareike Rasche, Emma Steidel, Martin Zimmermann, et al.
British Journal of Haematology|March 26, 2013
NADH dehydrogenase subunit 4 variant sequences in childhood acute myeloid leukaemiaMichael A Morgan, Birgit Markus, Malou Hermkens, et al.
Blood|June 21, 2003
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceChristian M Zwaan, Soheil Meshinchi, Jerald P Radich, et al.
Leukemia|October 16, 2023
Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALLŽeljko Antić, Alena van Bömmel, Konstantin Riege, et al.
Blood|September 25, 2007
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarrayNorihiko Kawamata, Seishi Ogawa, Martin Zimmermann, et al.
Cancers|November 27, 2021
Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved DiagnosticsPhilippe Chouvarine, Željko Antić, Jana Lentes, et al.
Haematologica|September 29, 2018
THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescentsJeanette Greiner, Martin Schrappe, Alexander Claviez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapseStephanie Ehlers, Christin Herbst, Martin Zimmermann, et al.
Pageof 28

Showing results (171-180 of 279) with videos related to

Sort By:
Pageof 28
Haematologica|August 10, 2012
IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocolPetra Dörge, Barbara Meissner, Martin Zimmermann, et al.
Pediatric Blood & Cancer|June 10, 2017
Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groupsUrsula Creutzig, Michael N Dworzak, Martin Zimmermann, et al.
Cancers|March 6, 2021
Second Relapse of Pediatric Patients with Acute Myeloid Leukemia: A Report on Current Treatment Strategies and Outcome of the AML-BFM Study GroupMareike Rasche, Emma Steidel, Martin Zimmermann, et al.
British Journal of Haematology|March 26, 2013
NADH dehydrogenase subunit 4 variant sequences in childhood acute myeloid leukaemiaMichael A Morgan, Birgit Markus, Malou Hermkens, et al.
Blood|June 21, 2003
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistanceChristian M Zwaan, Soheil Meshinchi, Jerald P Radich, et al.
Leukemia|October 16, 2023
Recurrent DNMT3B rearrangements are associated with unfavorable outcome in dicentric (9;20)-positive pediatric BCP-ALLŽeljko Antić, Alena van Bömmel, Konstantin Riege, et al.
Blood|September 25, 2007
Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarrayNorihiko Kawamata, Seishi Ogawa, Martin Zimmermann, et al.
Cancers|November 27, 2021
Transcriptional and Mutational Profiling of B-Other Acute Lymphoblastic Leukemia for Improved DiagnosticsPhilippe Chouvarine, Željko Antić, Jana Lentes, et al.
Haematologica|September 29, 2018
THROMBOTECT - a randomized study comparing low molecular weight heparin, antithrombin and unfractionated heparin for thromboprophylaxis during induction therapy of acute lymphoblastic leukemia in children and adolescentsJeanette Greiner, Martin Schrappe, Alexander Claviez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2010
Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapseStephanie Ehlers, Christin Herbst, Martin Zimmermann, et al.
Pageof 28